Tracking the Narrative for Esperion Therapeutics as Analyst Optimism Grows Amid Shifting Fundamentals [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
This adjustment comes as analysts show increasing optimism about the company's growth prospects and execution in its target markets. Stay tuned to discover key ways you can monitor shifts in the company narrative and stay ahead of future updates. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Esperion Therapeutics. What Wall Street Has Been Saying Analyst commentary on Esperion Therapeutics has been predominantly positive in recent updates, reflecting a cautiously optimistic outlook from research firms that cover the stock. ?? Bullish Takeaways Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target for Esperion Therapeutics to $9 from $7 and maintained an Overweight rating. This suggests increased confidence in the company's future performance. Analysts point to improved execution and growth momentum as key drivers behind this upward revision in valuation. The Overweight rating and hig
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ESPR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With DiabetesGlobeNewswire
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 1/12/26 - Form 8-K
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- ESPR's page on the SEC website